It is known that T1D involves a complex interaction between pancreatic β-cells and cells of both the innate and adaptive immune systems. Innate immune signaling is involved in the initiation of the autoimmune process, which results in the destruction of β cells by cytotoxic T cells during T1D pathogenesis. Here, we show that exposing human induced pluripotent stem cells derived β cells (hiPSC-β cells) to autologous peripheral immune cells in vitro reveals an activation signature of T1D β cell rejection across multiple immune cell types. We profiled innate and adaptive immune activated populations and identified relevant populations to T1D autoimmunity. After co-culture of donor-matched target and effector cells, we performed mass cytometry (CyTOF). We used an immunophenotyping CyTOF panel containing 32 markers to identify activation in different immune populations. As a negative control, we used unstimulated effector peripheral immune cells. As a positive control, we used unmatched β cells from other donors. Finally, all experiments were performed with hiPSC-α cells and donor-matched peripheral immune cells, and we did not observe the activation of immune cells in the hiPSC-α cells donor-matched coculture. Exposing T1D hiPSC-β cells to donor-matched peripheral immune cells in vitro revealed the activation of distinct immune cell populations that participate in T1D β cell rejection. We observed differences within T1D patient samples, we anticipate that we can use this model to study T1D patient heterogeneity.


N. Leite: None.


American Diabetes Association (1-19-PMF-024)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at